<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2744">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02820155</url>
  </required_header>
  <id_info>
    <org_study_id>201412002MIPD</org_study_id>
    <nct_id>NCT02820155</nct_id>
  </id_info>
  <brief_title>Phase I Single and Multiple Escalating Dose Study of RGN1016 in Healthy Male Subjects</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Dose-Escalating, Single Dose and Multiple Dose Study to Evaluate the Safety and Pharmacokinetics of RGN1016 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, placebo-controlled, dose-escalating, single dose and&#xD;
      multiple dose study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, randomized, placebo-controlled, dose-escalating study. The study&#xD;
      comprises single dose (Stage I) and multiple dose (Stage II) stages. Stage II will not be&#xD;
      initiated until completion of Stage I. The interim safety analysis report will be submitted&#xD;
      to TFDA for an approval for proceeding to Stage II.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of incidence of Adverse Events.</measure>
    <time_frame>up to14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak drug concentration (Tmax)</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life T1/2</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGN1016_50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGN1016_100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGN1016_200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGN1016_400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGN1016_800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RGN1016</intervention_name>
    <description>Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)</description>
    <arm_group_label>RGN1016_100mg</arm_group_label>
    <arm_group_label>RGN1016_200mg</arm_group_label>
    <arm_group_label>RGN1016_400mg</arm_group_label>
    <arm_group_label>RGN1016_50mg</arm_group_label>
    <arm_group_label>RGN1016_800mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects may be entered in the study only if they meet all of the following criteria:&#xD;
&#xD;
          1. Male with suitable veins for cannulation or repeated venipuncture, and must be able to&#xD;
             swallow the study drug intact;&#xD;
&#xD;
          2. Aged between 20 and 45 years (inclusive) at the screening visit;&#xD;
&#xD;
          3. Has normal hematology results at screening visit;&#xD;
&#xD;
               -  WBC: 3.54 ~ 9.06X10^3/μL&#xD;
&#xD;
               -  RBC: 4 ~ 5.52X10^6/μL&#xD;
&#xD;
               -  hemoglobin: 13.2 ~17.2 g/dL&#xD;
&#xD;
               -  hematocrit: 40.4 ~ 51.1%&#xD;
&#xD;
               -  platelet: 148 ~ 339X10^3/μL&#xD;
&#xD;
          4. Has normal biochemistry results at screening visit;&#xD;
&#xD;
               -  alkaline phosphatase: 34 ~ 104 U/L&#xD;
&#xD;
               -  total bilirubin: 0.3 ~ 1.0 mg/dL&#xD;
&#xD;
               -  AST: 8 ~ 31 U/L&#xD;
&#xD;
               -  ALT: 0 ~ 41 U/L&#xD;
&#xD;
               -  BUN: 7 ~ 25 mg/dL&#xD;
&#xD;
               -  creatinine: 0.6 ~ 1.3 mg/dL&#xD;
&#xD;
          5. Normal coagulation results at screening visit;&#xD;
&#xD;
               -  Prothrombin time/INR: 9.8 ~ 11.5 sec/0.92 ~ 1.09&#xD;
&#xD;
               -  PTT: 25.6~32.6 sec&#xD;
&#xD;
          6. Normal blood pressure (systolic blood pressure: 100 ~ 140 mmHg; diastolic blood&#xD;
             pressure: 60 ~ 90 mmHg) at screening visit or prior to administration of&#xD;
             investigational product;&#xD;
&#xD;
          7. Able to provide written informed consent and willing to comply with the study protocol&#xD;
             procedures and restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects must not satisfy any of the following criteria:&#xD;
&#xD;
          1. Has a body weight less than 50 kg and/or body mass index (BMI) less than 18 kg/m^2 or&#xD;
             greater than 30 kg/m^2 at the screening visit. Body mass index is determined as total&#xD;
             body weight/height^2 (kg/m^2);&#xD;
&#xD;
          2. Is not in good general health as judged by the Investigator based on medical history,&#xD;
             vital signs, physical examination, ECG, laboratory tests, and urinalysis at the&#xD;
             screening visit or prior to administration of investigational product;&#xD;
&#xD;
          3. Has a history or presence of any disease or condition known to interfere with the&#xD;
             absorption, distribution, metabolism, or excretion of drugs at the screening visit or&#xD;
             prior to administration of investigational product;&#xD;
&#xD;
          4. Has a clinically significant psychiatric, renal, hepatic, cardiovascular,&#xD;
             gastrointestinal, or neurologic disease at screening or prior to administration of&#xD;
             investigational product;&#xD;
&#xD;
          5. Is a smoker and/or has used nicotine-containing products within the last 6 months&#xD;
             prior to the screening visit;&#xD;
&#xD;
          6. Has a history of alcohol and/or drug abuse;&#xD;
&#xD;
          7. Participation of any clinical investigation during the last 60 days;&#xD;
&#xD;
          8. Blood donation of more than 250 mL within the past 12 weeks;&#xD;
&#xD;
          9. Excessive intake of caffeine containing drinks or food (more than 6 units of caffeine&#xD;
             per day). One caffeine unit is contained in the following items: 1 (177.4 mL) cup of&#xD;
             coffee, 2 (354.9 mL) cans of cola, 1 (354.9 mL) cup of tea, ½ (118.3 mL) cup of energy&#xD;
             drink (e.g., PAOLYTA B Liq. or WHISBIH Liq.) or 3 oz of chocolate;&#xD;
&#xD;
         10. Use of drugs with enzyme inducing properties such as St. John's Wort within 4 weeks&#xD;
             prior to dosing;&#xD;
&#xD;
         11. Has used prescription or nonprescription medication (except for occasional use of&#xD;
             paracetamol and nasal spray) or herbal remedies or vitamins or minerals within 2 weeks&#xD;
             or 5 half-lives of the drug, whichever is longer, prior to dosing;&#xD;
&#xD;
         12. Any intake of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade,&#xD;
             or other products containing grapefruit or Seville oranges within 7 days of the first&#xD;
             administration of study medication;&#xD;
&#xD;
         13. Male subjects who are unwilling to use barrier contraception in addition to having&#xD;
             their partner use another method of contraception, for the duration of the study and&#xD;
             for 3 months after dosing;&#xD;
&#xD;
         14. Has a positive result on screening for serum hepatitis B surface antigen (HBsAg),&#xD;
             hepatitis C antibody (HCV Ab), or human immunodeficiency virus (HIV);&#xD;
&#xD;
         15. Has received a blood transfusion within the last 6 months at screening;&#xD;
&#xD;
         16. Involved in the planning or conduct of the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming-Jang Chiu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurology department of National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming-Jang Chiu</last_name>
    <phone>+886-2-2312-3456</phone>
    <phone_ext>65339</phone_ext>
    <email>mjchiu@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Jang Chiu</last_name>
      <phone>+886-2-2312-3456</phone>
      <phone_ext>65339</phone_ext>
      <email>mjchiu@ntu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>June 3, 2016</study_first_submitted>
  <study_first_submitted_qc>June 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>July 5, 2016</last_update_submitted>
  <last_update_submitted_qc>July 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease,cognitive function</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

